Effective platform for the production of recombinant outer membrane vesicles in gram-negative bacteria

Anthicha Kunjantarachot,Teva Phanaksri

DOI: https://doi.org/10.4014/jmb.2003.03023

2020-05-31

Journal of Microbiology and Biotechnology

Abstract:Bacterial outer membrane vesicles (OMVs) typically contain multiple immunogenic molecules that include antigenic proteins, making them good candidates for vaccine development. In animal models, vaccination with OMVs has been shown to confer protective immune responses against many bacterial diseases. It is possible to genetically introduce heterologous protein antigens to the bacterial host that can then be produced and relocated to reside within the OMVs by means of the host secretion mechanisms. Accordingly, in this study we sought to develop a novel platform for recombinant OMV (rOMV) production in the widely used bacterial expression host species, <i>Escherichia coli</i>. Three different lipoprotein signal peptides including their Lol signals and tether sequences-from <i>Neisseria meningitidis</i> fHbp, <i>Leptospira interrogans</i> LipL32, and <i>Campylobactor jejuni</i> JlpA-were combined upstream to the GFPmut2 model protein, resulting in three recombinant plasmids. Pilot expression studies showed that the fusion between fHbp and GFPmut2 was the only promising construct; therefore, we used this construct for large-scale expression. After inducing recombinant protein expression, the nanovesicles were harvested from cell-free culture media by ultrafiltration and ultracentrifugation. Transmission electron microscopy demonstrated that the obtained rOMVs were closed, circular single-membrane particles, 20-200 nm in size. Western blotting confirmed the presence of GFPmut2 in the isolated vesicles. Collectively, although this is a non-optimized, proof-of-concept study, it demonstrates the feasibility of this platform in directing target proteins into the vesicles for OMV-based vaccine development.

biotechnology & applied microbiology,microbiology